• Nuvation Bio posted an announcement on updated Phase 2 data for safusidenib in grade 2 IDH1-mutant glioma.
• Confirmed ORR 51.9%; 36-month PFS rate 79.1%; median follow-up 38.8 months; median PFS not reached.
• Clinical program expansion outlined, including a new ex-U.S. Phase 3 study G307 ().
• New U.S. Phase 2 study G209 targets patients progressing on vorasidenib ().

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY07175) on July 20, 2026, and is solely responsible for the information contained therein.